U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag , as Treatment for Patients with Unresectable or Metastatic Melanoma Pharmaceutical Investing
ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors With Losses to Inquire About Securities Class Action Investigation - AUPH Pharmaceutical Investing
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm Pharmaceutical Investing
Merck's KEYTRUDA® Significantly Improved Disease-Free Survival Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression Life Science Investing
AbbVie Expands Immunology Portfolio in Canada as Health Canada approves SKYRIZI® for the Treatment of Adults with Active Psoriatic Arthritis Pharmaceutical Investing
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm Pharmaceutical Investing
Notice of Knight Therapeutics' Fourth Quarter and Year End 2021 Results Conference Call Pharmaceutical Investing
RINVOQ® Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis Pharmaceutical Investing
LYNPARZA® Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial Life Science Investing
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm Pharmaceutical Investing
BetterLife Obtains In Vivo PK Data for BETR-001 Confirming its Bioavailability in Brain Pharmaceutical Investing
